

### **REMARKS**

Applicants would like to thank Examiner Canella for discussing this case with Applicants' representative, Melissa Pytel, on the telephone on November 1, 2005. The claims have been amended as discussed. Applicants submit that the claims 1-3, 5-7 and 9-32, as pending upon entry of this amendment, are in condition for allowance.


### **Rejections under 35 U.S.C. §112, first paragraph**

The rejection of claims 27-32 under 35 U.S.C. §112, 1<sup>st</sup> paragraph was maintained. The Examiner alleges that the amendment of the claims to recite "wherein said polypeptide has [METH1 or] METH2 activity" does not sufficiently limit the claims by functional attributes. Although Applicants disagree, in the interest of advancing prosecution, the claims have been amended to recite "wherein said polypeptide is capable of inhibiting angiogenesis." Support for this amendment can be found, for example, at page 2, lines 8-9; page 5, lines 3-4; and page 136, lines 7-8.

### **CONCLUSION**

Applicants respectfully request that the remarks of the present response be entered and made of record in the present application. If any additional information is needed, Applicants respectfully request that the Examiner contact the undersigned to facilitate prosecution. The application is believed to be in condition for allowance and early notice to that effect is earnestly solicited. If a fee is required in connection with this paper, please charge Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted,



Melissa J. Pytel

(Reg. No. 41,512)

Date: December 6, 2005

**Human Genome Sciences, Inc.**  
14200 Shady Grove Road  
Rockville, MD 20850  
Telephone: (301) 610-5764

MMW/MJP/ba